The EMA Accepts Formycon’s MAA for FYB203 to Treat Neovascular Age-Related Macular Degeneration (AMD)
Shots:
- Formycon and its license partner Klinge Biopharma have received the EMA’s acceptance on the MAA submitted for FYB203 (biosimilar Eylea) for the treatment of AMD
- Eylea is a long-acting injectable form of aflibercept prescribed to be administered q2month or q4month after the initial dosing period for the treatment of neovascular wet AMD or other retinal diseases
- The company had previously launched Ranivision (FYB201, biosimilar ranibizumab) for the treatment of neovascular AMD and other retinal diseases in EU
Ref: FORMYCON | Image: FORMYCON
Related News:- Formycon and its License Partner Klinge Biopharma Reports the BLA Submission of FYB203 (Biosimilar, Eylea) to the EMA
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
